首页> 美国卫生研究院文献>other >Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients
【2h】

Challenges and strategies to facilitate formulation development of pediatric drug products: Safety qualification of excipients

机译:促进儿科药物制剂开发的挑战和策略:辅料的安全性鉴定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A public workshop entitled “Challenges and strategies to facilitate formulation development of pediatric drug products” focused on current status and gaps as well as recommendations for risk-based strategies to support the development of pediatric age-appropriate drug products. Representatives from industry, academia, and regulatory agencies discussed the issues within plenary, panel, and case-study breakout sessions. By enabling practical and meaningful discussion between scientists representing the diversity of involved disciplines (formulators, nonclinical scientists, clinicians, and regulators) and geographies (eg, US, EU), the Excipients Safety workshop session was successful in providing specific and key recommendations for defining paths forward. Leveraging orthogonal sources of data (eg. food industry, agro science), collaborative data sharing, and increased awareness of the existing sources such as the Safety and Toxicity of Excipients for Paediatrics (STEP) database will be important to address the gap in excipients knowledge needed for risk assessment. The importance of defining risk-based approaches to safety assessments for excipients vital to pediatric formulations was emphasized, as was the need for meaningful stakeholder (eg, patient, caregiver) engagement.
机译:题为“促进儿科药物制剂开发的挑战和战略”的公共研讨会着重于当前的现状和差距以及针对基于风险的战略的建议,以支持儿科年龄适合的药物产品的开发。行业,学术界和监管机构的代表在全体会议,小组讨论和个案研究分组会议中讨论了这些问题。通过使代表所涉学科(制定者,非临床科学家,临床医生和监管人员)和地区(例如,美国,欧盟)的多样性的科学家之间进行切实可行的有意义的讨论,“赋形剂安全性”研讨会成功地提出了明确定义的关键建议前进的道路。利用正交数据源(例如食品工业,农业科学),协作数据共享以及提高对现有数据源的认识,例如儿科药物赋形剂的安全性和毒性(STEP)数据库,对于解决辅料知识方面的差距将至关重要。风险评估需要。强调了定义对儿科制剂至关重要的辅料基于风险的方法进行安全性评估的重要性,强调了有意义的利益相关者(例如患者,护理人员)参与的必要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号